Vascular BioSciences Announces Key Addition to Molecular Diagnostics Team: Dr. Roy Williams of Burnham Institute Brings Bioinformatics Expertise
San Diego, Calif., October 12, 2007 – Vascular BioSciences announced today that Dr. Roy Williams, Ph.D., will join the company as a Special Consultant for Bioinformatics. Dr. Williams brings extensive expertise in bioinformatics and microarray analysis to the companys Molecular Diagnostics division.
Dr. Roy Williams, Ph.D., an experienced research scientist at the Burnham Institute for Medical Research, is an internationally recognized pioneer in genomics, microarray technology, and the computer based analysis of complex genome-wide datasets. Prior to joining the Burnham Institute, Dr. Williams was an important member of the Small Molecule Drug Discovery Group at Diversa Corp in San Diego, CA. Dr. Williams, who received his Ph.D. in Biochemistry from the University of Birmingham, United Kingdom, performed ground-breaking gene expression post-doctoral research at Stanford University, the University of Chicago, and the Pasteur Institute in Paris, France.
David Mann, CEO and Chairman of Vascular BioSciences, commented, “Dr. Williams is a brilliant scientist and a pleasure to work with. He provides the company with the necessary expertise to handle the large amounts of data generated in our analysis of endoarterial biopsy samples. Roy’s valuable skill set will greatly accelerate our efforts to provide personalized medicine to patients based on the molecular analysis of endoarterial biopsies. Roy will also be invaluable to our drug discovery efforts at VBS Pharmaceuticals.”
About Vascular BioSciences & VBS Pharmaceuticals
Vascular BioSciences, a diversified biomedical company based in San Diego, California, provides solutions for vascular–based diseases in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides diagnostic services, and advances therapies in order to improve outcomes for vascular–based disease patients.
A newly formed majority-owned subsidiary, VBS Pharmaceuticals, has been created to provide a framework for Vascular BioSciences to engage in drug discovery and pharmaceutical development targeting vascular-based diseases.